DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/76jnds/immunotherapy_in) has announced the addition of the "Immunotherapy in Oncology Drug Pipeline Update 2013" report to their offering.
Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators in oncology drug development into one source.
There are today 571 companies plus partners developing 1007 cancer immunotherapy drugs in 2500 developmental projects in cancer. In addition, there are 17 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 474 drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 413 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 387 out of the 391 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 65 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Targets
Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 387 out of the 391 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
Biological Structures
The identity of available biological structures on 243 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 2733 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/76jnds/immunotherapy_in
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
